Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,699 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Control Condition Clear all
Completed Phase 4 Interventional Results available

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

NCT01494532
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

NCT00303563
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
P38 Inhibitor (4), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Anniston, Alabama • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Not applicable Interventional Results available

Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI

NCT02057081
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Posttraumatic Stress Disorders, Depression
Interventions
Multifamily Group for mTBI for Couples, Group Health Education (GHE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 17, 2026, 8:03 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Social Intelligence Training for Custodial Grandfamilies

NCT03239977
View directory record Official record
Conditions
Emotional Intelligence, Quality of Life, Social Competence
Interventions
Online Social Intelligence Training, Attention Control (AC)
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
12 Years to 18 Years
Enrollment
680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 8:03 PM EDT
Not listed Phase 2 Interventional

Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease

NCT05122598
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
Interventions
COT, Sham
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
55 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 17, 2026, 8:03 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT01156051
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions
Guanfacine extended-release tablets, Placebo comparator
Drug
Lead sponsor
Children's Specialized Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Hamilton, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 17, 2026, 8:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Health Impact 360: Advancing Physical, Social, and Mental Health Toward Cardiovascular Disease Prevention in Community Settings

NCT07034352
View directory record Official record
Conditions
Health Promotion, Cardiovascular Health
Interventions
Health Impact 360, Usual care - Wait list control
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Detroit, Michigan • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 8:03 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 4 Interventional

Intermittent Versus Continuous Medication in the Treatment of HIV

NCT00001967
View directory record Official record
Conditions
HIV Infection
Interventions
HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 8:03 PM EDT
Not listed Not applicable Interventional

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

NCT01687764
View directory record Official record
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions
Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention
Other · Behavioral
Lead sponsor
Hospital de Clinicas de Porto Alegre
Other
Eligibility
7 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 17, 2026, 8:03 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Investigating Biological Markers, Targets, and Intervention for Mood Disorders

NCT04632498
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Stress
Interventions
Mindfulness Based Intervention
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Treatments to Improve Smoking Cessation Medication Adherence

NCT01120704
View directory record Official record
Conditions
Smoking, Smoking Cessation, Adherence, Nicotine Dependence, Motivation
Interventions
Short Term Combination Nicotine Replacement Therapy (patch + gum), Long Term Combination Nicotine Replacement Therapy (patch + gum), Intensive Maintenance Counseling, Cognitive Medication Adherence Counseling (CAM), Electronic Medication Monitoring Device (the Helping Hand) + Feedback, Automated Adherence Prompting Phone Calls
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865436
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Results available

Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease

NCT00646204
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Memantine, placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Not applicable Interventional

eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With MS

NCT03829267
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
eFIT Intervention, eJournal Intervention, Treatment as usual
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 17, 2026, 8:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

NCT03656536
View directory record Official record
Conditions
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions
Pemigatinib, Gemcitabine, Cisplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
36
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

NCT01382719
View directory record Official record
Conditions
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions
bremelanotide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 17, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728
View directory record Official record
Conditions
Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Asthma, Respiratory Infections
Interventions
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU
Drug
Lead sponsor
Gary M Brittenham, MD
Other
Eligibility
3 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 8:03 PM EDT
Completed No phase listed Observational

Dose-Response to Exercise in Women Aged 45-75 Years (DREW)

NCT00011193
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Postmenopausal, Overweight or Obese
Interventions
Exercise
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 17, 2026, 8:03 PM EDT
Recruiting Not applicable Interventional

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

NCT06809192
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 8:03 PM EDT